ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0G8X Immunovia Ab (publ)

191.40
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immunovia Ab (publ) LSE:0G8X London Ordinary Share SE0006091997 IMMUNOVIA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 191.40 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 1.15M -168.09M -7.4272 -0.02 3.39M

Invitation to Presentation of Immunovia´s Full Year Report 2018 on February 14, 2019

12/02/2019 2:06pm

PR Newswire (US)


Immunovia Ab (publ) (LSE:0G8X)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Immunovia Ab (publ) Charts.

LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --

Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 – 6:30 p.m. CET. Immunovia will publish the company's Full Year Report 2018 for the period January – December 2018 on Thursday, February 14, at 5:05 p.m. CET.

Mats Grahn, CEO will present Immunovia and comment on the Full Year Report 2018 followed by a Q&A-session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

SE: +46850558352
BE: +3226200547
CH: +41225675632
DE: +4969222220380
DK: +4578150109
FR: +33170750721
NL: +31207219495
NO: +4723500236
UK: +443333009035
US: +16467224956

For questions or interview bookings:
ir@immunovia.com  

There will be an MP3-file available at Immunovia's webpage under Investors/audio-galley (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-full-year-report-2018-on-february-14--2019,c2739332

The following files are available for download:

https://mb.cision.com/Main/13121/2739332/989764.pdf

Immunovia, PR Telconference Q4

Cision View original content:http://www.prnewswire.com/news-releases/invitation-to-presentation-of-immunovias-full-year-report-2018-on-february-14-2019-300794090.html

SOURCE Immunovia AB

Copyright 2019 PR Newswire

1 Year Immunovia Ab (publ) Chart

1 Year Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart

Your Recent History

Delayed Upgrade Clock